Q1 Earnings Forecast for CLRB Issued By Roth Capital

Cellectar Biosciences, Inc. (NASDAQ:CLRB) – Research analysts at Roth Capital issued their Q1 2025 earnings per share (EPS) estimates for shares of Cellectar Biosciences in a report released on Monday, November 18th. Roth Capital analyst J. Aschoff forecasts that the biopharmaceutical company will post earnings per share of ($0.26) for the quarter. The consensus estimate for Cellectar Biosciences’ current full-year earnings is ($1.57) per share.

Cellectar Biosciences (NASDAQ:CLRB) last posted its earnings results on Tuesday, October 29th. The biopharmaceutical company reported ($0.51) EPS for the quarter.

A number of other brokerages have also weighed in on CLRB. StockNews.com raised Cellectar Biosciences to a “sell” rating in a report on Thursday, September 26th. Oppenheimer lowered their target price on Cellectar Biosciences from $14.00 to $12.00 and set an “outperform” rating on the stock in a research note on Tuesday.

Cellectar Biosciences Price Performance

Shares of NASDAQ:CLRB opened at $1.56 on Wednesday. The business’s 50-day moving average is $2.06 and its 200 day moving average is $2.41. The firm has a market capitalization of $63.29 million, a P/E ratio of -0.62 and a beta of 1.00. Cellectar Biosciences has a 1 year low of $1.55 and a 1 year high of $4.45.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Geode Capital Management LLC boosted its position in Cellectar Biosciences by 3.3% during the third quarter. Geode Capital Management LLC now owns 352,452 shares of the biopharmaceutical company’s stock worth $754,000 after purchasing an additional 11,266 shares in the last quarter. Oppenheimer & Co. Inc. purchased a new stake in Cellectar Biosciences in the 3rd quarter worth $27,000. Sequoia Financial Advisors LLC purchased a new position in Cellectar Biosciences during the third quarter valued at $51,000. XTX Topco Ltd grew its position in shares of Cellectar Biosciences by 432.4% in the second quarter. XTX Topco Ltd now owns 63,304 shares of the biopharmaceutical company’s stock valued at $158,000 after purchasing an additional 51,413 shares during the period. Finally, AIGH Capital Management LLC raised its position in shares of Cellectar Biosciences by 8.2% during the 2nd quarter. AIGH Capital Management LLC now owns 3,036,187 shares of the biopharmaceutical company’s stock worth $7,590,000 after purchasing an additional 231,270 shares during the last quarter. Hedge funds and other institutional investors own 16.41% of the company’s stock.

About Cellectar Biosciences

Cellectar Biosciences, Inc, a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer.